Lexeo Therapeutics, Inc. (LXEO) — SEC Filings
Lexeo Therapeutics, Inc. (LXEO) — 48 SEC filings. Latest: 10-Q (May 11, 2026). Includes 22 8-K, 7 SC 13G/A, 6 10-Q.
View Lexeo Therapeutics, Inc. on SEC EDGAR
Overview
Lexeo Therapeutics, Inc. (LXEO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 30, 2026: Lexeo Therapeutics, Inc. (LXEO) reported no revenue for the fiscal year ended December 31, 2025, consistent with its clinical-stage status. The company is advancing a portfolio of gene therapy candidates, with LX2006 for Friedreich ataxia cardiomyopathy and LX2020 for PKP2-arrhythmogenic cardiomyopa
Sentiment Summary
Across 48 filings, the sentiment breakdown is: 46 neutral, 2 mixed. The dominant filing sentiment for Lexeo Therapeutics, Inc. is neutral.
Filing Type Overview
Lexeo Therapeutics, Inc. (LXEO) has filed 6 10-Q, 22 8-K, 1 ARS, 2 DEFA14A, 1 10-K, 1 10-Q/A, 2 DEF 14A, 7 SC 13G/A, 5 SC 13G, 1 S-1 with the SEC between Feb 2024 to May 2026.
Filings by Year
Recent SEC Filings (48)
Risk Profile
Risk Assessment: Of LXEO's 27 recent filings, 2 were flagged as high-risk, 10 as medium-risk, and 15 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | Not Disclosed |
| EPS | Not Disclosed |
| Debt-to-Equity | Not Disclosed |
| Cash Position | Not Disclosed |
| Operating Margin | Not Disclosed |
| Total Assets | Not Disclosed |
| Total Debt | Not Disclosed |
Key Executives
- Dr. Christopher Adams
- Ms. Sarah Kelly
- Mette Kirstine Agger
- Dr. David R. Walt
- Ms. Sarah E. Emens
- Dr. Frederick W. Telling
- Dr. Jennifer L. Adeler
Industry Context
Lexeo Therapeutics operates in the rapidly evolving gene therapy sector, focusing on cardiovascular indications. The industry is characterized by high unmet medical needs, significant scientific innovation, and substantial capital requirements. Key trends include the development of novel delivery vectors like AAV, advancements in manufacturing technologies to improve yield and purity, and a growing pipeline targeting rare and prevalent diseases. Competition comes from other biotechnology companies and pharmaceutical giants investing heavily in gene therapy research and development.
Top Tags
10-Q (4) · corporate-governance (4) · filing (4) · material-agreement (3) · equity-sale (3) · disclosure (3) · financials (3) · 8-K (3) · Gene Therapy (2) · Cardiovascular Disease (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Aggregate market value of common equity held by non-affiliates | $216.5 million | As of June 30, 2025, indicating company size and liquidity. |
| Shares of common stock outstanding | 74,087,063 | As of March 27, 2026, indicating current share count. |
| Estimated patients with FA cardiomyopathy in the United States | 5,000 | Target patient population for LX2006. |
| Estimated patients with PKP2-ACM in the United States | 60,000 | Target patient population for LX2020. |
| Date of positive interim clinical data for LX2006 | 2025-10 | Key milestone for LX2006 development. |
| Date of positive interim clinical data for LX2020 | 2026-01 | Key milestone for LX2020 development. |
| Date of registrational trial design submission for SUNRISE-FA 2 | 2026-02 | Critical regulatory step for LX2006. |
| GMP AAV production process scale | 200L | Demonstrates manufacturing scalability for larger patient populations. |
| Purified AAVrh.10 product yield | 1E15 vg/L | Indicates high efficiency of the Sf9-baculovirus manufacturing process. |
| Maximum empty capsids in purified AAVrh.10 product | 25% | Indicates high purity of the manufactured gene therapy product. |
| Q3 2025 Net Loss | $20.283M | 31.22% improvement from Q3 2024 |
| YTD 2025 Net Loss | $79.042M | 9.16% increase from YTD 2024 |
| Q3 2025 R&D Expenses | $15.695M | 33.00% decrease from Q3 2024 |
| Q3 2025 G&A Expenses | $5.953M | 26.69% decrease from Q3 2024 |
| Cash and Cash Equivalents | $40.996M | As of September 30, 2025, up from $35.014M at Dec 31, 2024 |
Frequently Asked Questions
What are the latest SEC filings for Lexeo Therapeutics, Inc. (LXEO)?
Lexeo Therapeutics, Inc. has 48 recent SEC filings from Feb 2024 to May 2026, including 22 8-K, 7 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of LXEO filings?
Across 48 filings, the sentiment breakdown is: 46 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Lexeo Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Lexeo Therapeutics, Inc. (LXEO) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Lexeo Therapeutics, Inc.?
Key financial highlights from Lexeo Therapeutics, Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for LXEO?
The investment thesis for LXEO includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Lexeo Therapeutics, Inc.?
Key executives identified across Lexeo Therapeutics, Inc.'s filings include Dr. Christopher Adams, Ms. Sarah Kelly, Mette Kirstine Agger, Dr. David R. Walt, Ms. Sarah E. Emens and 2 others.
What are the main risk factors for Lexeo Therapeutics, Inc. stock?
Of LXEO's 27 assessed filings, 2 were flagged high-risk, 10 medium-risk, and 15 low-risk.
What are recent predictions and forward guidance from Lexeo Therapeutics, Inc.?
Forward guidance and predictions for Lexeo Therapeutics, Inc. are extracted from SEC filings as they are enriched.